Literature DB >> 33751773

Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.

Vishnu Anand Cuddapah1, Holly A Dubbs1,2,3, Laura Adang1, Steven L Kugler1, Elizabeth M McCormick4, Zarazuela Zolkipli-Cunningham4,5, Xilma R Ortiz-González1,2,3, Shana McCormack6, Elaine Zackai5,7, Daniel J Licht1, Marni J Falk4,5, Eric D Marsh1,2,3.   

Abstract

Over the past decade, pathogenic variants in all members of the ASXL family of genes, ASXL1, ASXL2, and ASXL3, have been found to lead to clinically distinct but overlapping syndromes. Bohring-Opitz syndrome (BOPS) was first described as a clinical syndrome and later found to be associated with pathogenic variants in ASXL1. This syndrome is characterized by developmental delay, microcephaly, characteristic facies, hypotonia, and feeding difficulties. Subsequently, pathogenic variants in ASXL2 were found to lead to Shashi-Pena syndrome (SHAPNS) and in ASXL3 to lead to Bainbridge-Ropers syndrome (BRPS). While SHAPNS and BRPS share many core features with BOPS, there also seem to be emerging clear differences. Here, we present five cases of BOPS, one case of SHAPNS, and four cases of BRPS. By adding our cohort to the limited number of previously published patients, we review the overlapping features of ASXL-related diseases that bind them together, while focusing on the characteristics that make each neurodevelopmental syndrome unique. This will assist in diagnosis of these overlapping conditions and allow clinicians to more comprehensively counsel affected families.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  ASXL1; ASXL2; ASXL3; Bainbridge-Ropers syndrome; Bohring-Opitz syndrome; Shashi-Pena syndrome

Mesh:

Substances:

Year:  2021        PMID: 33751773      PMCID: PMC8842511          DOI: 10.1002/ajmg.a.62156

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.578


  28 in total

Review 1.  New cases of Bohring-Opitz syndrome, update, and critical review of the literature.

Authors:  Axel Bohring; Grétel G Oudesluijs; Dorothy K Grange; Giuseppe Zampino; Patrick Thierry
Journal:  Am J Med Genet A       Date:  2006-06-15       Impact factor: 2.802

Review 2.  [Bainbridge-Ropers syndrome with ASXL3 gene variation in a child and literature review].

Authors:  R Zhang; X H He; H Y Lin; X H Yang
Journal:  Zhonghua Er Ke Za Zhi       Date:  2018-02-02

3.  Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.

Authors:  Bianca Russell; Jennifer J Johnston; Leslie G Biesecker; Nancy Kramer; Angela Pickart; William Rhead; Wen-Hann Tan; Catherine A Brownstein; L Kate Clarkson; Amy Dobson; Avi Z Rosenberg; Samantha A Schrier Vergano; Benjamin M Helm; Rachel E Harrison; John M Graham
Journal:  Am J Med Genet A       Date:  2015-04-29       Impact factor: 2.802

4.  Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.

Authors:  Jiapeng Wang; Zhaomin Li; Yongzheng He; Feng Pan; Shi Chen; Steven Rhodes; Lihn Nguyen; Jin Yuan; Li Jiang; Xianlin Yang; Ophelia Weeks; Ziyue Liu; Jiehao Zhou; Hongyu Ni; Chen-Leng Cai; Mingjiang Xu; Feng-Chun Yang
Journal:  Blood       Date:  2013-11-19       Impact factor: 22.113

5.  Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition.

Authors:  Alma Kuechler; Johanna Christina Czeschik; Elisabeth Graf; Ute Grasshoff; Ulrike Hüffmeier; Tiffany Busa; Stefanie Beck-Woedl; Laurence Faivre; Jean-Baptiste Rivière; Ingrid Bader; Johannes Koch; André Reis; Ute Hehr; Olaf Rittinger; Wolfgang Sperl; Tobias B Haack; Thomas Wieland; Hartmut Engels; Holger Prokisch; Tim M Strom; Hermann-Josef Lüdecke; Dagmar Wieczorek
Journal:  Eur J Hum Genet       Date:  2016-11-30       Impact factor: 4.246

6.  Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations.

Authors:  Pamela Magini; Matteo Della Monica; Maria Luisa Giovannucci Uzielli; Patrizia Mongelli; Gloria Scarselli; Eleonora Gambineri; Gioacchino Scarano; Marco Seri
Journal:  Am J Med Genet A       Date:  2012-03-14       Impact factor: 2.802

7.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Authors:  Omar Abdel-Wahab; Mazhar Adli; Lindsay M LaFave; Jie Gao; Todd Hricik; Alan H Shih; Suveg Pandey; Jay P Patel; Young Rock Chung; Richard Koche; Fabiana Perna; Xinyang Zhao; Jordan E Taylor; Christopher Y Park; Martin Carroll; Ari Melnick; Stephen D Nimer; Jacob D Jaffe; Iannis Aifantis; Bradley E Bernstein; Ross L Levine
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

Review 8.  Functional and cancer genomics of ASXL family members.

Authors:  M Katoh
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

9.  De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies.

Authors:  Darrell L Dinwiddie; Sarah E Soden; Carol J Saunders; Neil A Miller; Emily G Farrow; Laurie D Smith; Stephen F Kingsmore
Journal:  BMC Med Genomics       Date:  2013-09-17       Impact factor: 3.063

10.  ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Authors:  Jean-Baptiste Micol; Alessandro Pastore; Daichi Inoue; Nicolas Duployez; Eunhee Kim; Stanley Chun-Wei Lee; Benjamin H Durham; Young Rock Chung; Hana Cho; Xiao Jing Zhang; Akihide Yoshimi; Andrei Krivtsov; Richard Koche; Eric Solary; Amit Sinha; Claude Preudhomme; Omar Abdel-Wahab
Journal:  Nat Commun       Date:  2017-05-18       Impact factor: 14.919

View more
  3 in total

Review 1.  Identification of differential microRNAs and messenger RNAs resulting from ASXL transcriptional regulator 3 knockdown during during heart development.

Authors:  Ze-Qun Liu; Mi Cheng; Fang Fu; Ru Li; Jin Han; Xin Yang; Qiong Deng; Lu-Shan Li; Ting-Ying Lei; Dong-Zhi Li; Can Liao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  DNA methylation signature associated with Bohring-Opitz syndrome: a new tool for functional classification of variants in ASXL genes.

Authors:  Zain Awamleh; Eric Chater-Diehl; Sanaa Choufani; Elizabeth Wei; Rebecca R Kianmahd; Anna Yu; Lauren Chad; Gregory Costain; Wen-Hann Tan; Stephen W Scherer; Valerie A Arboleda; Bianca E Russell; Rosanna Weksberg
Journal:  Eur J Hum Genet       Date:  2022-04-01       Impact factor: 5.351

Review 3.  ASXL1/2 mutations and myeloid malignancies.

Authors:  Edward A Medina; Caroline R Delma; Feng-Chun Yang
Journal:  J Hematol Oncol       Date:  2022-09-06       Impact factor: 23.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.